Categories: Wire Stories

JSR Life Sciences� Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy

Launch marks product�s first use in a commercial therapeutic

SUNNYVALE, Calif.–(BUSINESS WIRE)–JSR Life Sciences, LLC today announced that its lead product, Amsphere™ A3, has been incorporated for the first time into the commercial manufacturing of an FDA-approved treatment.

Amsphere™ A3 is a next generation Protein-A chromatography resin that enables advanced protein separation in downstream processing of therapeutic antibodies. Since its launch in January 2016, the product has seen rapid adoption as an alternative option for downstream purification in biologics processing.

“The support provided by our global applications teams really helped make this happen,” said Hideaki Nomura, general manager of JSR Life Sciences’ Bioprocess Division. “Despite international supply chain disruptions affecting most global companies, we are in a position not only to maintain our commitments, but to expand our bioprocess purification materials to support more biologics companies in their pursuit of promising treatments for patients.”

The company is currently expanding on all fronts to facilitate increased manufacturing of biologics. Along with its first commercial launch, Amsphere™ A3 is currently being used in more than 95 clinical programs worldwide.

About JSR Life Sciences, LLC

A business unit of JSR Corporation, JSR Life Sciences, LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR Life Sciences provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR Life Sciences offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR Life Sciences’ global network of affiliates includes Crown Bioscience Inc., KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com.

Contacts

Missy Bindseil

JSR Life Sciences Company Inquiries

Director, Marketing & Communications

mbindseil@jsr-nahq.com

Mike Beyer

JSR Life Sciences Media Inquiries

Sam Brown Inc.

mikebeyer@sambrown.com
+1 312-961-2502

Alex

Recent Posts

Hangzhou, China: Connecting International Youth to Museums Through Technology

HANGZHOU, CHINA - Media OutReach Newswire – 30 April 2025 - From April 23 to…

43 minutes ago

LUX Mash-Up: Reframing Bollywood Soundtracks With Empowering Clap-Backs

LUX and VML Singapore Create Entertaining Playlists That Spark Reflection on Gender Representation in Popular…

1 hour ago

Work+Store Expands Storage Solutions with Premium Wine Storage Service in Kallang Bahru

SINGAPORE - Media OutReach Newswire - 30 April 2025 - Work+Store, a leading provider of…

3 hours ago

Coda unveils ESG roadmap to drive data privacy, ethics, and sustainability

SINGAPORE - Media OutReach Newswire - 30 April 2025 - Coda, a leader in digital…

4 hours ago

Unlocking Diverse Test-Drive Experiences: GWM Stirs up the Shanghai Auto Show with Full-Scenario Test Drives

BAODING, CHINA - Media OutReach Newswire - 30 April 2025 - The 2025 Shanghai International…

5 hours ago

Schneider Electric advances in product environmental data transparency

Enabling customers to make better informed sustainability and business decisions 14 environmental data attributes now…

8 hours ago